Contents

List of tables

Table 1: National Immunisation Schedule, commencing 1 January 2017

Table 2: Funded vaccines for special groups

Table 1.1: Approximate basic reproduction numbers (in developed countries) and implied crude herd immunity thresholds for common vaccine-preventable diseases

Table 1.2: Classification of vaccines, with examples

Table 1.3: Suggested intervals between immunoglobulin (IG) product administration or blood transfusion and MMR or varicella vaccination (does not apply to rotavirus vaccine)

Table 1.4: Predicted numbers of coincident, temporally associated events after a single dose of a hypothetical vaccine, based on background incidence rates

Table 2.1: Key points for cold chain management

Table 2.2: Guidelines for vaccine administration

Table 2.3: Needle gauge and length, by site and age

Table 2.4: Common vaccine responses

Table 2.5: Signs and symptoms of anaphylaxis

Table 2.6: Distinguishing anaphylaxis from a faint (vasovagal reaction)

Table 2.7: Emergency equipment

Table 2.8: Initial anaphylaxis response/management

Table 2.9: AEFIs to be reported

Table 2.10: Primary immunisation requirements for adults (funded)

Table 2.11: Checklist for adult vaccination, excluding travel requirements

Table 3.1: Summary of suggested responses to concerns about immunisation

Table 4.1: Accelerated immunisation schedule (funded) for infants in whom liver or kidney transplant is likely

Table 4.2: Guidelines for live virus vaccine administration for individuals on high-dose corticosteroids

Table 4.3: Immunotherapy agents for immune-mediated inflammatory disease

Table 4.4: Additional vaccine recommendations (funded and unfunded) for HIV-positive individuals

Table 4.5: Additional vaccine recommendations (funded and unfunded) and schedules for individuals with functional or anatomical asplenia

Table 4.6: Recommended vaccines, by occupational group

Table 4.7: Recommended vaccines for those with lifestyle risk factors

Table 7.1: Hepatitis A vaccine recommendations

Table 7.2: Hepatitis A-containing vaccines: by age, dose and schedule

Table 7.3: Recommendations for post-exposure immunoprophylaxis of Hepatitis A virus (HAV)

Table 8.1: Hepatitis B vaccine recommendations, funded and unfunded

Table 8.2: Summary of funded hepatitis B vaccine doses and immunisation schedules

Table 8.3: Interpretation of serology for hepatitis B virus infection

Table 8.4: Hepatitis B immunoglobulin (HBIG) doses

Table 9.1: Average annual percentage of cancer cases attributable to HPV, by anatomic site and sex, United States, 2008–2010

Table 9.2: HPV vaccine recommendations and schedules

Table 10.1: Current estimates of TIV influenza vaccine efficacy and effectiveness

Table 10.2: Recommended influenza vaccine doses in children

Table 10.3: Influenza vaccine recommendations

Table 11.1: Complications from contracting measles, mumps and rubella diseases compared with MMR vaccine adverse effects

Table 12.1: Symptoms and signs of meningococcal disease

Table 12.2: Recommended antibiotics for suspected cases

Table 12.3: Notified cases and rates of meningococcal disease, 2008–2012

Table 12.4: Meningococcal vaccines registered and available in New Zealand

Table 12.5: Meningococcal group C conjugate (MenCCV) and quadrivalent meningococcal vaccine (MCV4-D) recommendations

Table 12.6: Suggested meningococcal schedule for non-high-risk children (not funded)

Table 14.1: Incidence (per 100,000 doses) of major adverse reaction following acellular pertussis vaccine

Table 14.2: Recommended antimicrobial therapy and post-exposure prophylaxis for pertussis in infants, children, adolescents and adults

Table 15.1: Summary of pneumococcal vaccine serotype content

Table 15.2: Decrease in rates of culture-positive invasive pneumococcal disease due to PCV7 serotypes between 2006–2007 and 2012, by age group

Table 15.3: Children aged under 18 years at high and increased risk of pneumococcal disease

Table 15.4: Adults (≥18 years) at high or increased risk of pneumococcal disease

Table 15.5: Summary of pneumococcal vaccine schedules

Table 17.1: Cochrane review: percentage of severe rotavirus and all-cause diarrhoea cases prevented in children by RV1 and RV5, compared to placebo (low mortality rate countries)

Table 18.1: Estimated morbidity and mortality associated with the 1963/64 US rubella epidemic

Table 18.2: Suggested roles of health professionals

Table 19.1: Immunisation schedule for tetanus-containing vaccines (excluding catch-up)

Table 19.2: Guide to tetanus prophylaxis in wound management

Table 20.1: Age-specific estimated risks for complications after administration of BCG vaccine

Table 21.1: High-risk groups eligible for funded varicella immunisation

Table 21.2: Dose of ZIG based on body weight

Table 21.3: Sequelae of congenital varicella

Table A1.1: Summary of when each vaccine was introduced to New Zealand

Table A1.2: July 2011 immunisation schedule

Table A1.3: June 2008 immunisation schedule

Table A1.4: February 2006 immunisation schedule

Table A1.5: February 2002 immunisation schedule

Table A1.6: January 2001 immunisation schedule

Table A1.7: August 2000 immunisation schedule

Table A1.8: 1996 immunisation schedule

Table A1.9: 1994 immunisation schedule

Table A1.10: 1984 immunisation schedule

Table A1.11: 1980 immunisation schedule

Table A1.12: 1971 immunisation schedule

Table A1.13: 1967 immunisation schedule

Table A1.14: 1961 immunisation schedule

Table A2.1: Minimum number of antigens required, by age at time of presentation, for children aged under 10 years

Table A2.2: Minimum number of antigens required by children aged 10 to under 18 years at the time of presentation

Table A2.3: Age at presentation: 3–6 months

Table A2.4: Age at presentation: 7–11 months

Table A2.5: Age at presentation: 12–23 months

Table A2.6: Age at presentation: 2 years to under 5 years

Table A2.7: Age at presentation: 5 years to under 10 years

Table A2.8: Age at presentation: 10 years to under 18 years – excluding HPV

Table A2.9: Age at presentation: 11 years to under 18 years – HPV only

Table A2.10: Primary immunisation requirements for adults aged 18 years and older

Table A6.1: Actions (and their frequency) to ensure safe vaccine handling and storage

Table A6.2: Recommendations for the use of vaccines exposed to temperatures outside +2oC to +8oC

Table A6.3: Preparing for vaccine transportation

Table A8.1: Case definitions for notifiable vaccine-preventable diseases

Table A8.2: Confirmatory laboratory tests for vaccine-preventable diseases